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which is critical for maintaining brain homeostasis and low permeability to control the passage
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However, the bloodebrain barrier also hinders the transportation of therapeutic agents and
contrast agents from the blood into brain tissue, lowering treatment efficiency. Recently,
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In this article, we review the current state of this drug delivery technique, its application in
preclinical brain disease models, and treatment planning for this novel technique.
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Concept of the bloodebrain barrier
The bloodebrain barrier (BBB) was first discovered by Paul
Ehrlich [1]. He noted that when he administrated a dye into
an in vivo circulatory system, all the organs were stained
except for the brain and the spinal cord. Further evidence
of the BBB was provided by Max Lewandowsky [2] and Edwin
Goldmann [3]. Lewandowsky [2] discovered the limitedof Ultrasound in Medicine. All rights reserved.
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Goldmann [3] noticed that when he directly injected trypan
blue dye into the cerebrospinal fluid, only cells within the
brain were stained. Although these findings offered in-
dications for the presence of the BBB, the concept of the
BBB was confirmed by Davson and Spaziani [4], who
demonstrated that cerebral capillaries prevent the diffu-
sion of sucrose, iodide, and p-aminohippurate into the
brain. In 1967, Reese and Karnovsky [5] designed further
experiments to visualize the BBB using horseradish
peroxidase.
Structure of the BBB
The capillary network within the brain is extremely packed
(about 20 m2/1300 g in human brain [6]) and is intricate.
Thus, each neuron is perfused by its own microvasculature
[7]. The BBB is a specialized substructure within the central
nervous system (CNS) blood vascular system, which consists
of endothelial cells (ECs) connected together by tight
junctions (TJs), basement membranes, pericytes, and as-
trocytes [8]. This layered structure acts as the brain’s
frontline defense against toxic and harmful materials in the
blood stream. The TJs are located in the cerebrovascular
endothelium, which contains membrane-associated guany-
late kinases such as cingulin, occludin, and the cadhedrins
(single-pass membrane-spanning molecules) ZO-1 and ZO-2
[9]. The presence of TJs prevents circulating substances
from entering the brain via paracellular routes, although
they can reach the brain through the ECs of brain micro-
vessels via a transcellular pathway or via specialized
receptor-mediated transcytosis and transport proteins [10].
The basement membrane supports the abluminal surface of
the astrocytes, ECs, and pericytes [11]. The combination of
ECs, astrocyte feet, and pericytes makes the BBB less
permeable to large-molecular-weight (>500 Da) [12],
water-soluble, and ionic substances [13]. Therefore, the
BBB prevents nearly 100% of macromolecule therapeutic
drugs and diagnostic substances, and about 98% of small-
molecule agents from penetrating the brain, which is a
great disadvantage for the treatment of CNS disease [14].
Methods for increasing BBB permeability
There are a number of preclinical and clinical approaches
for crossing the BBB to enhance drug delivery into the brain
tissue, including: (1) chemical modification of drugs to
make them lipophilic, (2) use of drug carriers to transport
drugs across the BBB, (3) intravenous (i.v.) administration
of hypertonic solutions to open the BBB, and (4) direct
transcranial injection of drugs through a needle or catheter
to bypass the BBB structure and reach the brain. In
approach (1), the drug is modified with lipid-soluble func-
tional groups (e.g., amino acids) or conjugated to lipid
carriers (e.g., free fatty acid, adamantane, or dihyropyr-
idine) to achieve drug lipidization. However, the main
problem with drug lipidization lies in the increased uptake
of the lipidized drug by peripheral organs, reducing the
drug concentration in the brain tumor [7]. In approach (2),
the drug is encapsulated into carriers (e.g., liposomes or
nanoparticles [15]), or conjugated to proteins [16], peptidevectors [17], or antibodies [18]. These drug carrier devices
then promote the transportation of the drug across the BBB
using a BBB endogenous-carrier system and/or a receptor-
mediated transcytosis route. Due to the finite amount of
receptors in vivo and the limited payload of a drug carrier,
the drug carrier approach is limited by inadequate trans-
portation of the drug. In approach (3), the infusion of
hyperosmotic solution (e.g., mannitol and arabinose) in-
duces shrinkage of the brain and brain capillary ECs, and
thus leads to a transient opening of the TJs [19]. However,
this method induces nonlocalized drug delivery as well as
promotes the penetration of toxic substance into the brain
tissues (e.g., plasma albumin or other blood protein com-
ponents), thereby causing damage to surrounding normal
brain cells and neural cells [20]. In approach (4), the drug is
directly delivered to the brain via either an intra-
cerebroventricular injection or an intracerebral implanta-
tion [21]. Nevertheless, the drug can only penetrate the
brain tissue via diffusion, which makes it difficult to cover
the whole lesion from the depot site. Further, this method
may produce invasive traumas during the injection process.Therapeutic effect of focused ultrasound
The piezoelectric materials of an ultrasound probe can be
manufactured into an arc shape, or electric phase modu-
lation can be used to focus transmitted ultrasound energy,
thus enabling focused ultrasound (FUS). FUS allows nonin-
vasive accumulation of acoustic energy within a focal spot
inside the body, with negligible biological effects to the
surrounding tissues and near-fields. There are two kinds of
mechanisms for inducing biological effects by FUS, thermal
and nonthermal (e.g., cavitation), both of which are dis-
cussed below.
When exposing biological tissues to FUS for long dura-
tions, the acoustic energy is attenuated and absorbed by
the surrounding tissues, and then converted into thermal
energy, producing a regional temperature rise. This
temperature-rising phenomenon has been shown to persist
for minutes to hours, and is further introduced in treatment
applications, called hyperthermia. However, previous
studies have indicated that temperatures in the range of
43e46C have detrimental effects on the brain tissue such
as ammonia production, hemiparesis, and even death [22].
By contrast, tumor cells are believed to be particularly
sensitive to heat, and therefore, FUS-induced hyperthermia
(at 43C for 30e60 minutes) can be used to increase the
sensitivity of tumors to other interventions (radiation
therapy, chemotherapy, and immunotherapy) used to treat
cancers [23]. At higher temperatures (>60C), FUS is also
applied as a thermal ablation procedure to defeat solid
tumors. Many studies have demonstrated the feasibility of
using thermal ablation to remedy a variety of tumors,
including kidney, uterus, liver, breast, bone, pancreas, and
prostate [24,25]. In addition, thermal coagulation of blood
vessels has also been proposed as a medical application of
FUS [26,27].
One major limitation of ultrasound-induced thermal
therapy in the brain is the strong absorption and attenua-
tion of acoustic energy by the skull. Therefore, for clinical
brain therapeutic application, an invasive craniotomy is
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parenchyma has been proposed by using a phased array
system to minimize the attenuation and distortion of ul-
trasound waves caused by the skull [28,29]. The optimal
frequency of transcranial sonication is confirmed to be
<1 MHz [29]; however, due to its larger focal spot and
reduced pressure gain, low-frequency ultrasound does not
allow energy focusing as sharply as high frequency does,
thus making it possible to overheat the skull [30].
Many studies have reported that acoustic-driven cavi-
tation can be used to enhance tissue heating during FUS
sonication [31]. Unlike rigid particles, the highly
compressible shell of microbubbles (MBs) enables oscilla-
tion (i.e., MBs can expand and contract in size) in response
to the pressure changes of a FUS pulse. There are two
modes of cavitation when the MBs are placed in an ultra-
sound field: stable and inertial cavitation. Stable cavitation
causes MBs to oscillate coherently with the incident ultra-
sound pulse, resulting in the generation of not only
nonlinear harmonic ultrasound waves of the transmitted
fundamental frequency [i.e., half the fundamental fre-
quency (subharmonics), 2-fold of the fundamental fre-
quency (2nd harmonics), etc.] [32], but also strong liquid
flows around the MBs (e.g., microstream) [33]. At higher
acoustic pressures, the MBs grow rapidly during the rare-
faction phase of ultrasound and violently collapse due to
the inertia of the inrushing fluid. This type of cavitation is
referred to as inertial cavitation. The collapse of MBs splits
them into many smaller MBs and even fragmentations,
producing wideband signals that are usually recognized as a
signature of inertial cavitation. During the inertial cavita-
tion, shock waves and transient high temperature (report-
edly up to 5000 K) are generated in the fluid nearby the
MBs. In addition, the liquid jet formation is located close to
the cell membrane, increasing the permeability of the cell
[34]. Furthermore, many groups have demonstrated the
in vivo applications of combing MBs and FUS to achieve
local, temporary, and reversible BBB opening [35].
Interaction between FUS and MBs within brain
tissue
Combining MBs and FUS-induced BBB opening for
CNS drug delivery
Over a decade ago, Hynynen et al [36] proposed an inno-
vative method utilizing FUS in combination with gas-filled
MBs that were injected into the blood stream prior to FUS
sonication, to noninvasively, restorably, and locally induce
BBB opening. Although FUS itself has been approved to
open the BBB, the addition of MBs reduces the ultrasound
energy required for BBB opening, decreasing the probability
of occurrence of thermal damage to the brain. This phe-
nomenon has been supported by several reports demon-
strating that the FUS-sonicated MBs are restrained in the
blood vessels; hence, the elicited biological effects should
be confined to the vessel walls [37,38]. Compared to other
traditional brain drug delivery approaches such as hyper-
tonic infusion of modified lipophilic chemicals, the combi-
nation of MBs with FUS is a totally noninvasive and local
procedure, thus minimizing undesired off-target effects.Further, this recoverable MB-enhanced FUS-induced BBB
opening (MB-FUS-BBB opening) technique provides a time
window of several hours that not only is beneficial to the
transportation of drugs into the CNS, but also allows
enhanced permeability and retention of drugs, specifically
in the tumor. This technique provides an attractive choice
for increasing the local concentration of chemotherapeutic
drug for the treatment of CNS disease and brain tumors.
The feasibility of applying MB-FUS-BBB opening tech-
nique in large animals has been widely investigated by
various groups. Xie et al [38] first applied this technique in
the pig model, and confirmed that either albumin-coated
perfluorocarbon MBs or lipid-encapsulated perfluoro-
carbon MBs combined with transtemporal unfocused 1-MHz
FUS sonication successfully increased BBB permeability
transiently. Another study conducted by Liu et al [39]
showed that BBB opening can be transtemporally ach-
ieved in swine using very-low-frequency ultrasound
(28 kHz) with a planar transducer. After performing crani-
otomy, the distribution and penetration depth of delivered
superparamagnetic iron oxide (SPIO) within brain tissue
were further enhanced. However, the low-frequency ul-
trasound resulted in off-target effects, since ultrasound
waves reflect within the skull cavity.
Nonhuman primate MB-FUS-BBB opening has also been
studied. McDannold et al [40] showed that repeated and
recoverable BBB opening was achieved in rhesus macaques.
In addition, none of the animals that underwent the BBB
opening process had evident histological or functional
damage. Another initial study by Marquet et al [41]
demonstrated the feasibility of combing two different
types of MBs (customized 4e5 mm and Definity) with
500 kHz FUS in primates. It is noteworthy that in the pri-
mate model, monitoring of the transcranial cavitation
during BBB opening can still be achieved by a passive
cavitation detector. Tung et al [42] also reported the
feasibility of transcranial, cavitation-guided BBB opening in
a monkey. However, the number of cases and data for
successful BBB openings are limited. Moreover, prior studies
lack histological confirmation or cognitive test results.Cellular mechanisms of MBeFUSeBBB opening
There are four possible routes by which macromolecules
can cross the BBB after FUS is performed with MBs: (1)
transcytosis; (2) transendothelial cell cytoplasmic open-
ings; (3) interendothelial clefts via opening of a part of the
TJs; and (4) free passage through the damaged EC lining
[43]. After BBB opening, active vesicular transport occurs
first [44]. Several electron microscopy studies have re-
ported that the vesicle number within the ECs of the BBB
[43e45] and bloodetumor barrier (BTB) [46] increases
following FUS sonication. Furthermore, the interactions of
FUS and MBs transiently upregulate the caveolae proteins
within the BTB and the BBB [45,46].
The other mechanism for transfer of macromolecules
into the brain parenchyma is paracellular passage through
the interendothelial clefts and opened TJs. The former has
been visualized by electron microscopy [47], and proteins
of TJ (e.g., claudin-1, claudin-5, ZO-1, and occludin) are
downregulated in the FUS-induced BBB opening region
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tion of AKT (also known as protein kinase B), which may
change the integrity of TJs [49]. Both in vitro and in vivo
studies demonstrated that ion imbalances (e.g., Ca2þ)
induced by FUS are associated with cellular sonoporation
reorganization of gap junction proteins [50].
By contrast, in vivo microvasculature dynamic imaging
during BBB opening has been conducted by multiphoton
microscopy [51]. Both vasoconstriction and vasodilation
have been reported after applying MBs and FUS; however,
vasoconstriction seems to appear only in arterioles [52]. In
addition, leakage of the agent (i.e., dyes) after MB-FUS-BBB
opening can be divided into three categories: (1) fast; (2)
sustained; and (3) slow [53]. Choe et al showed that fast
leakage brought about a rapid enhancement in dye signal
intensity within the extravasculature, reaching a peak
within 1 minute after MB-FUS-BBB opening, followed by a
quick decrease. This type of leakage occurred in case of all
vessels sizes and acoustic pressures (0.0710.25 MPa) in
their study. In addition, this leakage occurred at the vessel
wall with point sources. The leakage response of sustained
leakage resembled fast leakage, but the dye signal intensity
kept increasing after FUS sonication, which lasted for 1 hour.
Sustained leakage occurred at low-to-intermediate pres-
sures (0.0710.13 MPa), and compared to fast leakage,
sustained leakage involved vessels of similar diameters, but
within in a smaller range of sizes. Ultimately, slow leakage
happened 515 minutes after applying FUS irradiation with
low acoustic pressures (0.0710.1 MPa) and was more
prevalent among small vessels (<25 mm).Bioeffects of FUS and MBs
Notwithstanding the abovementioned benefits of MB-FUS-
BBB opening, there is still a concern that the inertial
cavitation that occurs during the BBB opening process may
generate high-velocity jets, shock waves, and free radicals
that should damage the ambient cellular structures, pro-
ducing undesired complications within the sonicated loca-
tion, including intracerebral hemorrhage (ICH), transient
blood-supply shortage, cellular inflammation response, and
cell apoptosis [53,54]. Many studies have indicated that the
occurrence of ICH is associated with most of the immediate
and delayed brain injuries [55]. Furthermore, the ICH limits
the permeability of the BBB, decreasing the efficiency of
drug delivery into the brain [56].
There are several reasons why ICH induces brain in-
juries: (1) chemical toxicity from the hematoma or the
mechanical forces that appear during hematoma formation
may cause cellular apoptosis and necrosis adjacent to the
ICH regions [57]; (2) formation of edema following ICH in-
creases intracranial pressure and produces herniation [58];
(3) the cerebral metabolic rate of oxygen and cerebral
blood flow decrease around the ICH zone [59]; (4) thrombin
production immediately after ICH may cause inflammatory
cell infiltration and brain edema [60]; (5) erythrocyte lysis
occurs during the formation of the membrane attack com-
plex after activation of the complement cascade and
depletion of intracellular energy [61]; (6) overloading of
iron in the ICH area causes local epileptiform paroxysmal
discharges [62]; and (7) the interaction between thrombinand iron may damage the brain after ICH because thrombin
upregulates the transferrin receptor of the brain, causing
excessive iron uptake into the cells [63].
MB-FUS-BBB opening for enhanced delivery of
agents into the brain
There have been a number of efforts to deliver molecules
across an intact BBB by MB-FUS-BBB opening with preclini-
cal setups. Trypan blue (872.8 Da) and Evans blue
(960.8 Da) dyes are extensively utilized to confirm suc-
cessful BBB opening [64,65]. In addition, gadolinium-based
contrast agents (Gd, 500e900 Da) used for magnetic reso-
nance imaging (MRI) are frequently administrated to
confirm the site and efficiency of the BBB opening [66,67].
Other imaging tracers such as horseradish peroxidase
(40 kDa) [68,69], Alexa Fluoro 488 (10 kDa) [50], mono-
crystalline iron oxide nanoparticles (10 kDa) [51], Texas
red-tagged dextran (3e70 kDa) [52,70], lanthanum chloride
(139 Da) [69], 99mTc diethylenetriaminepentaacetate
(492 Da) [70], SPIO (60 nm) [71], Mn2þ [72], and gold
nanorods [73] all have been delivered across the BBB.
In terms of therapeutic molecules and antitumor drugs
(Table 1), Kinoshita et al [74] successfully delivered Her-
ceptin (150 kDa) and D4 receptor antibodies (150 kDa) into
mouse brain tissues [65]. Treat et al [75] demonstrated
successful delivery of doxorubicin (DOX) (543 Da) into
normal rat brain through MB-FUS-BBB opening. Wu et al [76]
reported that the level of methotrexate (545.44 Da) that
accumulated into the brain by MB-FUS-BBB opening was
higher than that by intracarotid injection. Several studies
have also shown that deposition of liposomal DOX, 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU), temozolomide,
and boronophenylalanine can also be enhanced by MB-FUS-
BBB opening in a rat glioma model [56,77e80].
In addition, many studies have focused on the delivery of
other therapeutic substances (e.g., DNA, antibody, macro-
phage, or stem cells) into the brain. The antiamyloid-b an-
tibodies (150 kDa) and BAM-10 antibodies can also cross the
BBB in a mouse model of Alzheimer’s disease (AD) [81,82].
Recently, neural stem cells have been transported into brain
by an MB-FUS-BBB opening technique [83]. Burgess et al
[84,85] showed that the siRNA can be noninvasively deliv-
ered into the striatum by MB-FUS-BBB opening in a mouse
model of Huntington’s disease (HD). The feasibility of
transferring brain-derived neurotrophic factor by DNA-
loaded MBs and FUS for gene therapy in the brain has been
conducted by Huang et al [86]. In virus-based gene delivery,
Hsu et al [87] showed that following MB-FUS-BBB opening,
the recombinant adeno-associated viral vectors can be
noninvasively and locally delivered into brain tissues,
achieving the goal of targeted gene delivery.
Treatment efficiency of MB-FUS-BBB opening
on brain disease models
Brain tumor
Despite the enhanced delivery of agents by MB-FUS-BBB
opening, it is also important to demonstrate the
Table 1 Summary of therapeutic agents that have been
delivered across the BBB or BTB by MB-FUS-BBB opening.
Therapeutic
agent
Use Animal model
Herceptin Anticancer
antibody
Normal brain [74]
Breast cancer brain
model [93]
D4 receptor
antibodies
Treating CNS
disease
Normal brain [65]
DOX Treating brain
tumor
Normal brain [75]
Methotrexate Treating brain
tumor
Normal brain [76]
Liposomal DOX Treating brain
tumor
Gliosarcoma
model [77]
BCNU Treating brain
tumor
Glioblastoma
model [56]
Temozolomide Treating brain
tumor
Glioblastoma
model [78]
Boronophenylalanine Treating brain
tumor
Gliosarcoma
model [80]
Anti-Ab antibodies Treating AD AD model [81]
Anti-Ab antibodies Treating AD AD model [82]
Stem cells Gene therapy Normal brain [83]
siRNA Treating HD HD model [84]
siRNA Treating HD HD model [85]
pBDNF-EGFP-N1 Gene therapy Normal brain [86]
Adeno-associated
virus
Gene therapy Normal brain [87]
Epirubicin in
magnetic
nanoparticles
Treating brain
tumor
Gliosarcoma
model [95]
BCNUeVEGFa Treating brain
tumor
Glioblastoma
model [128]
DOXeSPIOa Treating brain
tumor
Glioblastoma
model [94]
BCNUa Treating brain
tumor
Glioblastoma
model [129]
BCNUa Treating brain
tumor
Normal brain [123]
GDNFa Treating brain
injury
Neonatal rat
brain [99]
GDNFa Treating PD PD model [100]
AD Z Alzheimer’s disease; BBB Z bloodebrain barrier;
BTB Z bloodetumor barrier; CNS Z central nervous system;
FUS Z focused ultrasound; GDNF Z glial cell-derived neuro-
trophic factor; HDZ Huntington’s disease; MBZ microbubble;
PDZ Parkinson’s disease; SPIOZ superparamagnetic iron oxide;
VEGFZ vascular endothelial growth factor; DOXZ doxorubicin;
BCNUZ 1,3-bis(2-chloroethyl)-1-nitrosourea.
a Drug-loaded microbubbles were used.
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Brain tumors (including glioma, glioblastoma multiforme,
medulloblastoma, and astrocytoma) exhibit high lethality,
but the incidence is low compared to that of other cancers.
In the United States, nearly 18,000 patients are identified
with malignant brain tumor, and more than half of them
have Glioblastoma multiforme (GBM) [88]. Generally, the
patients with low-grade gliomas have a median survival of5e15 years. However, because of the poor prognosis of
high-grade gliomas (e.g., GBM), the median survival of the
patients is only 9e12 months [89]. In addition, most brain
tumors may recur locally within the site of the original
lesion [78].
Chemotherapy is a widespread treatment choice for
brain tumor. However, the major obstacle to brain tumor
chemotherapy is the BTB, which is the BBB surrounding the
tumor with a few different characteristics from the BBB
[90]. Permeability of the BTB within the brain tumor is
highly heterogeneous and is associated with tumor regions,
resulting in the extraordinarily variable BTB integrity within
different areas of the same tumor [91,92]. Generally, the
leakiest region of the BTB in a malignant brain tumor is
often present in the core of the tumor, while the BTB
structure at the peripheral edge of the proliferating tumor
is relatively intact [93]. The appearance of the BTB around
the brain tumor not only hampers the treatment outcome
on BBB intact tumor-infiltrating regions (typically in the
tumor peripheral), but also serves as a critical reason for
high GBM recurrence. Thus, one of the essential issues for
brain tumor therapy is to further increase the BBB integrity
of the tumor periphery. Liu et al [56] and Fan et al [94]
indicated that the permeability of BTB can be further
increased by FUS and MBs. Several studies have shown that
the combination of FUS and MBs can enhance the pene-
tration of drugs across the BTB to control tumor progression
and prolong animal survival, in an orthotopic rodent model
of glioblastoma multiforme [56,77,78]. Park et al [93]
further demonstrated that the growth inhibition of meta-
static brain tumors can be improved by this technique. Liu
et al [56] showed that with MB-FUS-BBB opening, the
amount of free BCNU accumulated within rat C6 glioma
tumor was enhanced. They also showed that magnetic
nanoparticles (6e12 nm) conjugated with epirubicin
(543.5 Da) can be successfully delivered to rat C6 glioma
tumor, causing a reduction in tumor size [95]. Recently,
their group demonstrated that the local concentration of
temozolomide can be increased by performing MB-FUS-BBB
opening, thus improving the control of tumor progression
and animal survival [81]. Other recent studies have pre-
sented enhanced delivery of boronophenylalanine by MB-
FUS-BBB opening, increasing the treatment efficiency of
boron neutron capture therapy for the rat GBM model and
9L gliosarcoma tumor rat model [82,83].
While these studies have shown positive results in terms
of an antitumor effect, there are still many issues that need
to be investigated. The first factor is that the penetration
area of the drugs should include infiltrating tumor cells.
Novel orthotopic models only provide limited tumor infil-
trating zones, so it is essential to evaluate the therapeutic
efficiency of tumor regions that are outside of the FUS
sonication area. The second factor is related to the pa-
rameters of FUS. Liu et al [56] have demonstrated that
overexcitation of FUS can induce the occurrence of ICH,
which leads to BCNU hydrolysis, thereby decreasing the
amount of drug entering the brain. However, MB-FUS-BBB
opening induced cellar inflammation, which has been re-
ported to have an antitumor effect [96]. Therefore, opti-
mization of FUS parameters should be the next issue for
improving tumor treatment outcome. This technique can
open the BBB transiently and the blood lifetime of the drug
188 C.-H. Fan, C.-K. Yehis limited, so selecting a time point that can maximize the
amount of drug entering the whole tumor cell is the third
issue. Although many questions remain to be answered, the
advancement of this technology will contribute significantly
to brain neuro-oncology treatments.
Parkinson’s disease
In addition to applications in the treatment of brain tumors,
the feasibility and treatment effect of MB-FUS-BBB opening
should be discussed for CNS neurodegenerative diseases.
Parkinson’s disease (PD) is a neurodegenerative disease
associated with depleted dopamine production, which
causes tremor, muscular rigidity, bradykinesia, gait diffi-
culty, akinesia, and even death of part of the brain in the
most serious cases [97]. The available symptomatic treat-
ments for PD currently include medical and surgical mo-
dalities and gene therapy, of which surgery is an extremely
invasive and highly complex approach. Medication primarily
focuses on dopamine supplementation to relieve the motor
symptoms [98]. The clinical effectiveness of dopamine,
however, is limited by the BBB, which prevents the drugs
from entering the brain parenchyma. Moreover, as the
neuron degeneration progresses, the medical management
of PD becomes more complex and medications become less
effective. Therefore, development of an endogenous
dopamine generative mechanism is an urgent consideration
for PD, and gene-based techniques have recently been
proposed to replace missing or dysfunctional genes in order
to synthesize dopamine. Glial cell-derived neurotrophic
factor (GDNF) has been shown to provide a neuroprotective
effect in PD rats. Wang et al [99] first proposed lipid-coated
GDNF-loaded MBs. With sonication of FUS, these MBs can
release GDNF to ameliorate hypoxiaeischemia injury in
neonatal rats. In 2014, they investigated the neuro-
protective effect by further applying this treatment
method to a PD rat model. Their results showed that this
treatment method reduced apomorphine-induced rota-
tions, and increased striatal dopamine and nigral tyrosine
hydroxylase levels in PD rats 4 weeks after performing the
treatment [100]. While levodopa remains the most effec-
tive drug in the treatment of PD, long-term levodopa
administration causes dyskinesia, which has hindered its
use in PD patients. The ultrasound-induced lipid-coated
GDNF MBs constitute another effective drug therapy for the
treatment of PD.
Alzheimer’s disease
AD is characterized as a neurodegenerative and progressive
disease without available treatment in aged humans. The
clinical symptoms of AD include gradual decline in cognitive
function, memory loss, trouble with language, and mood
swings [101,102]. The pathogenesis of AD is believed to be
driven by the production and accumulation of the hyper-
phosphorylated tau and beta-amyloid (Ab), which aggre-
gate and form tau tangles, amyloid, and plaques [103].
Current therapeutic and diagnostic management is focused
on reducing and discovering Ab aggregates [104,105]. The
common treatment of AD patients is the long-term i.v. in-
jection of high doses of anti-Ab antibody to clear Abplaques in the brain [106]. However, only 0.1% of injected
antibodies arrive in the lesion in this way [107]. Other de-
livery methods include direct delivery of anti-Ab antibody
into the cortex by intracranial injection or skull removal
[105,108]. Although the plaques can be reduced within a
few days, the drawback of these procedures is its invasive
nature. Raymond et al [82] first demonstrated that MB-FUS-
BBB opening allows the delivery of both small antibodies
and molecules in the AD mouse model (B6C3-tg). The
treatment efficiency of MB-FUS-BBB opening with immu-
notherapy for a different AD mouse model (TgCRND8) was
evaluated by Jorda˜o et al [81]. They showed that Ab pla-
ques were significantly reduced 4 days after treatment with
a lower dose of antibody than used in previous studies.
Recently, Jorda˜o et al [109] observed that Ab plaque size
and number were significantly reduced within 4 days
following the process of MB-FUS-BBB opening in TgCRND8
mice. In 2014, Burgess et al [110] validated that repeated
MB-FUS-BBB opening targeted to the hippocampus could
modulate pathologic abnormalities, plasticity, and behavior
in the same animal model. There are two potential mech-
anisms for FUS-enhanced Ab internalization and clearance.
First, opening of the BBB permits the entry of endogenous
immunoglobulin G and immunoglobulin M from the periph-
ery into the brain. Second, FUS causes activation of astro-
cytes and microglia. By contrast, properties of cerebral
vessels in AD mouse and healthy mouse were investigated
by two-photon microscopy and fluorescent dextran [111].
Burgess et al [111] noticed that the change in cerebral
vascular diameter might depend on BBB permeability, and
the occurrence of Ab plaques might reduce the perme-
ability of a vessel after FUS sonication because the plaques
deposited on the vessel wall weaken the vessel structure
and reduce the elastic properties. Their results revealed
the impact of vascular amyloid on the MB-FUS-BBB opening,
thus increasing the safety of this technique for AD patients
in the future.Huntington’s disease
HD is a dominantly inherited neurodegenerative disorder.
The mechanism of HD is an unstable expansion of a CAG
triplet repeat stretch within the Huntingtin (Htt) gene
[112]. This mutation results in a variant HTT protein that
gradually produces cell death and neuronal dysfunction in
the brain. Symptoms of HD are motor dysfunction, cognitive
decline, and progressive emotional changes. While HD is
monogenic and the etiology is known, there is still no
available treatment. Tetrabenazine is approved for
reducing the severity of its symptoms, but the side effects
include akathisia, depression, and dizziness [113,114]. In
addition, drug efficiency decreases as HD progresses.
Recently, because RNA interference can specifically reduce
the expression of the mutant Htt, gene therapy has been
proposed for the treatment of HD [115]. However, due to its
high molecular weight, the RNA does not pass through the
BBB, and thus delivery into the brain is limited to direct CNS
delivery. Burgess et al [85] have shown, in a rat HD model,
that the MB-FUS-BBB opening is an effective strategy for
noninvasively delivering cholesterol-conjugated small
interfering RNA to the striatum. In addition, their data
MB-Enhanced FUS-Induced BBB Opening 189illustrated that a significant reduction of Htt expression can
be observed 48 hours after treatment and this reduction in
Htt expression is higher when the extent of BBB opening is
increased. This study was a good beginning for demon-
strating that RNA treatment for knockdown of mutant Htt is
feasible without surgical delivery to the brain.Techniques to plan, monitor, and estimate MB-
FUS-BBB opening
Treatment plan and consideration
The first condition that should be considered prior to using
MB-FUS-BBB opening in an animal model is the accuracy. In
general, accurate FUS sonication can be conducted with
stereotactic frames [67]. Relying on trustworthy and
repeatable data, FUS can be delivered into a targeted brain
location without imaging guidance through a craniotomy.
Hynynen et al [36] first demonstrated a MRI-guidance FUS
system for precisely targeting and monitoring of trans-
cranial MB-FUS-BBB opening by MRI guidance. The second
concern is the occurrence of standing waves during trans-
cranial sonication. Standing waves can be eliminated by a
wideband composite sharply focused transducer and a
reduced duty cycle to disrupt the BBB without brain dam-
age [116].
The major obstacle of applying this approach to human is
the skull. Due to the thickness and irregular shape of the
skull, the FUS beam passing through different parts of the
skull can be deflected and distorted [117]. In addition, the
high attenuation of FUS would lead to a rise in the temper-
ature of the skull. The hemispherical phased array proposed
by Clement et al [118] can solve these problems. First, the
driving frequency of this array was 665 kHz, thus lowering
energy absorption by the skull bone. Second, this array
consisted of 64 elements that can be driven individually to
correct for beam aberrations. Third, the temperature of the
outer skull surface and scalp would be controlled within a
safe range using an active cooling system.
The BBB opening effect was conducted by FUS and
circulating MBs within vessels. Therefore, the intensity and
the bioeffect rely on the vascularity of the targeted tissue
[43]. It is essential to identify the location of FUS sonication
for avoiding critical regions and large vessels. In addition, it
is also important to know the perfusion ability and vascular
morphology of the sonication area for optimizing FUS
treatment.
Treatment monitoring and control
After successful delivery of agents by the process of MB-
FUS-BBB opening in an animal model, developing the
methods for imaging this procedure will be the next
important issue for applying this technique clinically. In
addition, the imaging methods should not only provide the
information of BBB opening, but also indicate the appear-
ance of brain damage for increasing the safety of this
technique. The first imaging modality to achieve this goal
was MRI. Several studies have demonstrated that contrast-
enhanced T1-weighted MRI with i.v. administration ofgadopentetate dimeglumine can be used to detect and
evaluate BBB opening [39,110]. Kinetics of the BBB
permeability can be measured by dynamic contrast-
enhanced MRI [119]. The occurrence of ICH or inflamma-
tion caused by FUS can be visualized by T2*- or
susceptibility-weighted MRI with superparamagnetic iron
oxide nanoparticles [38,74,120]. However, performing
multiple MRI sequence acquisitions and acquiring high-
quality images may cost on the order of minutes, restrict-
ing the use of MRI for dynamically observing the physiologic
changes of BBB disruption with a temporal resolution of <1
second.
Ultrasound imaging has many properties such as high
spatial resolution, and real-time and convenient imaging
for various types of diagnoses. In combination with MBs, the
sensitivity of ultrasound imaging can be enhanced suitably
to detect the dynamic change of microcirculation and
microperfusion within the brain. Goertz et al [121] first
attempted to monitor the MB-FUS-BBB opening by deter-
mining the changes in the timeeintensity curve of concur-
rent clinical ultrasound imaging. Fan et al [122] used MB
destructionereplenishment timeeintensity curve analysis
to estimate the perfusion kinetic map for determining the
scale and distribution of MB-FUS-BBB opening with a com-
mercial ultrasound imaging system (Vevo2100; VisualSonics,
Toronto, Ontario, Canada). Their results indicated that the
perfusion kinetic map could provide high detection sensi-
tivity and precision, and was highly correlated with moni-
toring via MRI. In addition, the occurrence of ICH also can
be detected by this ultrasound imaging strategy. Although
there are many limitations to the study (such as craniotomy
essential and time of MB administration), this approach still
provides a new opportunity to pursue ultrasound-monitored
MB-FUS-BBB opening and can be a potentially valuable
alternative for estimating the distribution of drug delivery.
The cavitation effect of MBs has been recognized as the
major mechanism underlying the MB-FUS-BBB opening. To
distinguish between the frequency components of the ac-
quired acoustic cavitation signals emitted by oscillating MBs
during the BBB opening process, the occurrence of BBB
opening and brain damage should be predicted and classi-
fied in real time. McDannold et al [53] first demonstrated
that the inertial cavitation is not responsible for the MB-
FUS-BBB opening, and the second and third harmonics of
the ultrasound driving frequency may indicate when BBB
opening takes place. Tung et al [42,54] further showed that
the cavitation activity during MB-FUS-BBB opening could be
acquired in nonhuman primates and rodents, and inertial
cavitation is not essential for BBB opening. Fan et al [123]
classified the roles of stable and inertial cavitation activ-
ities during the MB-FUS-BBB opening process by matching
the frequency of FUS sonication with that of self-made
submicron bubbles. They verified that stable cavitation
induces BBB opening, and inertial cavitation results in brain
damage. They also proposed that inertial cavitation can be
reduced by matching the frequency of FUS and the resonant
frequency of MBs, ensuring the safety of BBB opening.
O’Reilly and Hynynen [124] constructed a control algorithm
to automatically adjust the acoustic pressure of FUS after
each ultrasound pulse, based on acoustic emission signals
captured during each burst and processed prior to the next
pulse. The system can create safe BBB opening with little or
190 C.-H. Fan, C.-K. Yehno petechiae. The potential of cavitation-guided BBB
opening had been wildly explored in these studies, and the
feasibility of clinical applications should be investigated in
the future.
Treatment evaluation
Despite that fact that many imaging modalities can provide
the information underlying MB-FUS-BBB opening, the dis-
tribution and concentration of delivered drug within the
brain is still difficult to estimate. Several studies have
shown the correlation between signal intensity of
contrasted-enhanced T1 weighted MRI and the drug con-
centration of brain after sonication [77,78,125]. Drug de-
liveries were also found to be related to the vascular
transfer coefficients, via analysis of dynamic contrast-
enhanced MRI [126,127]. By contrast, uptake of drugs and
their penetration into the brain can be tracked if the drugs
are directly labeled with a contrast agent for MRI or other
imaging modality. Liu et al [95] showed the therapeutic
magnetic nanoparticles not only enhance deposition in the
brain, but also allow monitoring by MRI, enabling quantifi-
cation of their distribution in vivo. Fan et al [94] fabricated
SPIO-conjugated, doxorubicin-loaded MBs. After perform-
ing FUS sonication, the multifunctional MBs can concur-
rently open the BBB, release DOX, and act as dual
ultrasound and MRI contrast agents. Due to the SPIO,
nanoparticles can be monitored by MRI, and the distribution
of drug can be detected and quantified during or after FUS-
induced drug delivery. If the relationship between the
concentration of the drug and the imaging contrast agents
is revealed, we can predict the delivered drug level and
therapeutic response in animal brain.
Conclusion
The first proof-of-concept study for demonstrating the
capability of MB-FUS-BBB opening in animal models was
conducted in 2001. So far, the efficiency of drug delivery
and the mechanism of MB-FUS-BBB opening have been
extensively investigated in normal and CNS disease animal
models. This technique can be used to perform noninvasive
and transient drug delivery at targeted areas without the
occurrence of brain damage. Many imaging modalities and
methods have been developed for planning, detecting, and
estimating drug delivery after performing MB-FUS-BBB
opening. In addition, there have been many preclinical
studies investigating its safety issues in large animals,
application of FUS to human skulls, and stability of the FUS
sonication device. Taken together, results from prior
studies demonstrate that this drug delivery procedure is
ready for clinical tests.
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